Plasma kallikrein inhibitors

Patent metadata

Field	Value
Publication number	US-2024190892-A1
Application number	US-202218550332-A
Country	US
Kind code	A1
Filing date	Mar 16, 2022
Priority date	Mar 18, 2021
Publication date	Jun 13, 2024
Grant date	—

Abstract

The present invention provides a compound of formula I and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing one or more disease states that could benefit from inhibition of plasma kallikrein, including hereditary angioedema, uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. The compounds are selective inhibitors of plasma kallikrein.

First claim

1 . A compound of the Formula I:

wherein X is —CH 2 —, —NH(C═O)CH 2 — or —(C═O)NHCH 2 —;

is phenyl or heteroaryl, which can be monocyclic or bicyclic, wherein said phenyl is optionally substituted with halo and said heteroaryl is optionally substituted with halo, hydroxy, C 1-6 alkyl or oxo;
R 1 is selected from the group consisting of hydrogen, halo, hydroxy and C 1-6 alkyl;
R 2 is selected from the group consisting of hydrogen, halo, hydroxy and C 1-6 alkyl;
R 3 is selected from the group consisting of hydrogen, heterocyclyl, which can be monocyclic or bicyclic, heteroaryl and NR 4 R 5 , wherein said heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of oxo and C 1-6 alkyl and said heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and R x ;
R 4 is selected from the group consisting of hydrogen, cyclopropyl and C 1-6 alkyl;
R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and cyano;
R x is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and methoxy;
n is an integer from zero to two;
or a pharmaceutically acceptable salt thereof.

2 . The compound of claim 1 wherein X is —(C═O) NHCH 2 —, or a pharmaceutically acceptable salt thereof.

3 . The compound of claim 1 of the Formula Ia:

R 1 is selected from the group consisting of hydrogen, halo, hydroxy and C 1-6 alkyl;
R 2 is selected from the group consisting of hydrogen, halo, hydroxy and C 1-6 alkyl;
R 3 is selected from the group consisting of hydrogen, heterocyclyl, which can be monocyclic or bicyclic, heteroaryl and NR 4 R 5 , wherein said heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of oxo and C 1-6 alkyl and said heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and R x ;
R 4 is selected from the group consisting of hydrogen, cyclopropyl and C 1-6 alkyl;
R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and cyano;
R x is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and methoxy;
n is an integer from zero to two;

or a pharmaceutically acceptable salt thereof.

4 . The compound of claim 1 of the Formula 1b:

R 3 is selected from the group consisting of hydrogen, heterocyclyl, which can be monocyclic or bicyclic, heteroaryl and NR 4 R 5 , wherein said heteroaryl is optionally substituted with one or two substituents independently selected from the group consisting of oxo and C 1-6 alkyl and said heterocyclyl is optionally substituted with one to three substituents independently selected from the group consisting of halo, hydroxy, cyano and R x ;
R 4 is selected from the group consisting of hydrogen, cyclopropyl and C 1-6 alkyl;
R 5 is selected from the group consisting of hydrogen and C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and cyano;
R x is hydrogen or C 1-6 alkyl, which is optionally substituted with one to three substituents selected from the group consisting of halo, hydroxy and methoxy;
n is an integer from zero to two;

or a pharmaceutically acceptable salt thereof.

5 . The compound of claim 1 wherein R 1 is halo and R 2 is halo, or a pharmaceutically acceptable salt thereof.

6 . The compound of claim 1 wherein n is zero, and R 3 is heterocyclyl, which is optionally substituted with one to three halo, or R x , or a pharmaceutically acceptable salt thereof.

7 . The compound of claim 1 wherein n is one, and R 3 is heteroaryl, which is optionally substituted with methyl or oxo, or a pharmaceutically acceptable salt thereof.

8 . The compound of claim 1 wherein R 4 is hydrogen, cyclopropyl or methyl, and R 5 is C 1-6 alkyl, which is optionally substituted with one to three halo, or cyano, or a pharmaceutically acceptable salt thereof.

9 . The compound of claim 1 selected from any one of compounds 1-52, or a pharmaceutically acceptable salt thereof.

10 . A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

11 . A method for treating impaired visual activity, diabetic retinopathy, diabetic macular edema, retinal vein occlusion, hereditary angioedema, diabetes, pancreatitis, cerebral hemorrhage, nephropathy, cardiomyopathy, neuropathy, inflammatory bowel disease, arthritis, inflammation, septic shock, hypotension, cancer, adult respiratory distress syndrome, disseminated intravascular coagulation, blood coagulation during cardiopulmonary bypass surgery, or bleeding from postoperative surgery in a mammal, comprising administering a composition of claim 10 to a mammal in need of thereof.

12 . A method for treating uveitis, posterior uveitis, wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy or retinal vein occlusion in a mammal comprising administering a composition of claim 10 to a mammal in need thereof.

13 . A method of treating diabetic retinopathy or diabetic macular edema in a mammal comprising administering a composition of claim 10 to a mammal in need thereof.

14 . A method of treating retinal vein occlusion in a mammal comprising administering a composition of claim 10 to a mammal in need thereof.

15 . (canceled)

16 . (canceled)

17 . The composition of claim 10 further comprising another agent selected from the group consisting of anti-inflammatory agents, anti-VEGF agents, immunosuppressive agents, anticoagulants, antiplatelet agents, and thrombolytic agents.

18 . The method of claim 11 further comprising another agent selected from the group consisting of anti-inflammatory agents, anti-VEGF agents, immunosuppressive agents, anticoagulants, antiplatelet agents, and thrombolytic agents.

Assignees

• Cernaka Natalija
• Ogawa Anthony K
• Cheng Alan C
• Bao Jianming
• Sharp Phillip Patrick
• Lopez Jovan Alexander
• Xiao Dong
• Tang Haiqun
• Merck Sharp & Dohme Llc

Inventors

• Cernaka Natalija
• Ogawa Anthony K
• Cheng Alan C
• Bao Jianming
• Sharp Phillip Patrick
• Lopez Jovan Alexander
• Xiao Dong
• Tang Haiqun

Classifications

• C07D519/00

  Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/5386

  spiro-condensed or forming part of bridged ring systems · CPC title

• C07D498/20 Primary

  Spiro-condensed systems · CPC title

• A61P27/02

  Ophthalmic agents · CPC title